Conquering Acute Respiratory Distress Syndrome ARDS and Cancer - Faron Pharmaceuticals

Endothelial barrier is everything

We all face life threatening conditions, if we lose the key property of vasculature - the endothelial barrier. Faron has identified several molecular mechanisms involved in the control of endothelial functions, providing opportunities to develop new unique drugs for true unmet medical need.

Read on ›
Drug development to save lives

Faron's lead drug platform Traumakine prevents vascular leakage through the injured endothelium of several central organs, potentially saving lives of seriously ill patients, e.g. those having acute respiratory distress syndrome (ARDS). The Clevegen project aims at recovering tumour immunity to help the host fight tumour growth and spread by controlling one of the key regulatory pathways connected to several cancers.

Read on ›
World-class expert network

Faron sources innovations from Academia and has built a strong expert network to execute drug development programs. The key opinion leaders play a crucial role in every step of our work, from inventions to clinical protocols and dissemination of results.

Read on ›
Many value inflection points in near future

Faron wants to create shareholder value, not only by advancing the pipeline but also by optimizing commercial steps of Faron products in various territories. Faron has already limited territorial licenses but retains all rights in Europe and USA for all proprietary drug candidates under development.

Read on ›

Lean Drug Development Company

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. Faron is based in Turku, Finland. Faron is listed on AIM under the ticker ‘FARN’.

READ ON ›

TRAUMAKINE Phase III study targeting the treatment of ARDS

Faron has entered into pan-European pivotal Phase III study with its lead candidate Traumakine®, which targets the treatment of Acute Respiratory Distress Syndrome (ARDS). This study, called INTEREST, aims to achieve conditional European approval and has received €6 million European Union Framework Programme funding (FP7). Currently there is no available drug treatment for ARDS, an orphan lung disease which has a high 30–45% mortality rate.

READ ON ›

Faron 2016 Final Results

READ ON ›

Recent news

29.3.2017
TURKU – FINLAND, 29 March 2017 Faron Pharmaceuticals Ltd (”Faron”) (LON: FARN), the clinical stage biopharmaceutical company, today reports its full year audited results for the year ended 31 December 2016. The 2016 Annual Report and Accounts become available in mid-April in digital form on the Company's website together with the invitation to the Annual General Meeting (AGM).
7.3.2017
TURKU – FINLAND, 7 March 2017 - Faron Pharmaceuticals Ltd (”Faron”) (LON: FARN), the clinical stage biopharmaceutical company, will be announcing its full year audited results for the year ended 31 December 2016 on Wednesday 29 March 2017.
1.3.2017
TURKU – FINLAND, 11.30 A.M. GMT, 1 March 2017 – Faron Pharmaceuticals Oy (“Faron” or "Company") (LON: FARN), the clinical stage biopharmaceutical company, is pleased to announce that, following the announcement on 28 February 2017, the proposed Placing and Subscription has been subscribed in full, in fulfilment of the Placee Condition, and all subscription monies have now been received by the Company. Pursuant to the Placing and Subscription, the Company is raising approximately £5.0 million before expenses by way of the Placing of 1,362,340 Placing Shares and the Subscription of 60,000 Subscription Shares at the Issue Price of 350 pence per share.

VIEW MORE ›

Traumakine video

Find out the Traumakine® mechanism of action, presented by Professor Geoff Bellingan, medical director at University College London Hospitals (UCLH), who led the Phase II trial.